Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | JAK2 V617F |
| Therapy | LGH447 + Ribociclib + Ruxolitinib |
| Indication/Tumor Type | leukemia |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| JAK2 V617F | leukemia | predicted - sensitive | LGH447 + Ribociclib + Ruxolitinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, combination treatment with Jakafi (ruxolitinib), LGH447, and Kisqali (ribociclib) led to complete tumor regression in a cell line xenograft model of leukemia harboring JAK2 V617F (PMID: 33782031). | 33782031 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (33782031) | Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms. | Full reference... |